Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Status unconfirmed · Phase 2 · Has a placebo group
Conditions studied: Gastric Carcinoma
In brief
This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.
Key facts
- Study ID
- NCT01573468
- Run by
- Genta Incorporated
- People needed
- 580
- Starts
- 2012-04-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2012-07-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Krankenhaus Nordwest — Frankfurt, Germany (enrolling)
- National Cheng Kung University Hospital — Tainan, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.